anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
For the colouring, enhancement of food value and improvement of the keeping properties of fats there are employed fat-soluble products obtained by finely disintegrating fresh carrots, directly emulsifying the disintegrated carrot by agitation in oil or fat, and treating the emulsion to isolate the oil or fat phase from the aqueous phase and from the structural substance of the carrot. According to an example, there is incorporated in freshly-made butter 1 per cent of a product made by pulping 10 kg. of carrots in a hammer or cross-beater mill, heating the pulp to 50 DEG  C. and emulsifying it by means of a high speed agitator with 1.5 kg. of butter fat, filtering the emulsion through a cloth in a hydraulic press, completely separating the oil phase by centrifuging, and removing ethereal oil from the oil phase by steam or with the aid of carbon dioxide or nitrogen, under reduced pressure if desired.ALSO:From carrots are obtained fat-soluble products containing in particular the provitamin A and vitamin E constituents of the carrot, which products are to be employed for the colouring, enhancement of physiological value and improvement of the keeping properties of fats and oils, fat-containing foods such as milk, and ointments and the like containing fat and water, by finely disintegrating fresh carrots, directly emulsifying the disintegrated carrot by agitation in oil or fat, and treating this emulsion to isolate the oil or fat phase from the aqueous phase and from the structural substance of the carrot.  The disintegration, emulsification or phase separation may be effected by subjection to supersonic vibration.  According to one example, 10 kg. of carrots are pulped in a hammer or cross-beater mill, the pulp is heated to 50 DEG C and emulsified in a high-speed agitator with 1.5 kg. of butter fat, the emulsion is filtered through a cloth in a hydraulic press, the oil phase is completely separated by centrifuging, and ethereal oil is removed from the oil phase by steam or with the aid of nitrogen or carbon dioxide, under reduced pressure if desired: the product may be incorporated, in the proportion of 1 per cent, in freshly-made butter, or may be employed in cosmetics.  According to another example, pieces of carrot are passed through a mincing machine and the minced carrots are treated in a continuous flow process with olive oil: the product may be incorporated, in proportions up to 10 per cent, in an ointment.
In view of dose-dependent adverse reactions and since pregabalin is eliminated primarily by renal excretion, adjust the dose in adult patients with reduced renal function. The use of pregabalin in pediatric patients with compromised renal function has not been studied.

Base the dose adjustment in patients with renal impairment on creatinine clearance (CLcr), as indicated in Table 2. To use this dosing table, an estimate of the patient’s CLcr in mL/min is needed. CLcr in mL/min may be estimated from serum creatinine (mg/dL) determination using the Cockcroft and Gault equation:

Next, refer to the Dosage and Administration section to determine the recommended total daily dose based on indication, for a patient with normal renal function (CLcr greater than or equal to 60 mL/min). Then refer to Table 2 to determine the corresponding renal adjusted dose.

(For example: A patient initiating pregabalin therapy for postherpetic neuralgia with normal renal function (CLcr greater than or equal to 60 mL/min), receives a total daily dose of 150 mg/day pregabalin. Therefore, a renal impaired patient with a CLcr of 50 mL/min would receive a total daily dose of 75 mg/day pregabalin administered in two or three divided doses.)

For patients undergoing hemodialysis, adjust the pregabalin daily dose based on renal function. In addition to the daily dose adjustment, administer a supplemental dose immediately following every 4-hour hemodialysis treatment (see Table 2).
Intrahospital transfer (IHT), a routine in the management of neurocritical patients requiring imaging or interventions, might affect brain metabolism. Studies about IHT effects using microdialysis (MD) have produced conflicting results. In these studies, only the most damaged hemisphere was monitored, and those may not reflect the impact of IHT on overall brain metabolism, nor do they address differences between the hemispheres. Herein we aimed to quantify the effect of IHT on brain metabolism by monitoring both hemispheres with bilateral MD. In this study, 27 patients with severe brain injury (10 traumatic brain injury and 17 subarachnoid hemorrhage patients) were included, with a total of 67 IHT. Glucose, glycerol, pyruvate and lactate were measured by MD in both hemispheres for 10 h pre- and post-IHT. Alterations in metabolite levels after IHT were observed on both hemispheres; although these changes were more marked in hemisphere A (most damaged) than B (less damaged). Our results suggest that brain metabolism is altered after an IHT of neurocritical ill patients particularly but not limited to the damaged hemisphere. Bilateral monitorization may be more sensitive than unilateral monitorization for detecting metabolic disturbances not directly related to the course of the disease.
An agent for colouring keratinous fibres, in particular human hair, containing, at least one direct dye, (a) at least one amphoteric surfactant, preferably an alkylbetaine, and (b) at least one alkylpolyglycoside, such that the content of amphoteric surfactant (b) in the agent - with respect to the total weight of the agent - is greater than the content of non-ionic surfactant (a). Preferably the amphoteric surfactant is cocamidopropylbetaine and the alkylglycoside is laurylglycoside. Ideally no sodium chloride or anionic surfactant is present in the composition. In some embodiments, non-ionic thickeners such as cellulose derivatives, gums, alginates, starches, clays and acrylate-polymers may be included. The most preferable thickener is cetylhydroxyethylcellulose. Film-forming agents in the form of cationic polyquaternium compounds, preferably polyquaternium-37, may also be incorporated. The use of the agent to colour keratinous fibres, as well as to a method in which the agent is applied are also disclosed.
MTD of CPI-613® from initiation of treatment to 30 days after treatment. MTD will be determined by testing increasing doses of CPI-613®, starting from 500 mg/m\^2 and up to 1,500 mg/m\^2, on dose escalation cohorts of three patients (maximum 24 patients) in combination with Gem-RT therapy. MTD reflects the highest drug dose that does not cause unacceptable adverse effects, with a target dose-limiting toxicity (DLT) rate of 30%. Final dose will be revised as appropriate.
FIELD: medicine, vaccines. SUBSTANCE: vaccine has diphtheritic, tetanic, whooping cough antigens and a conjugate of fragments of capsule polysaccharides from Haemophilus influenza type b and protein CRM 197  in a single immunizing dose in pharmaceutically acceptable carrier. Diphtheritic and tetanic antigens can be in the form of the corresponding anatoxin. Whooping cough antigen can be in the form of inactivated cells Bordetella pertussis. Diphtheritic and tetanic anatoxins are adsorbed on aluminium phosphate. Inactivated cells Bordetella pertussis are administrated as suspension with potassium dihydrogen phosphate, sodium hydrogen phosphate and sodium chloride. The mixed vaccine is used for children vaccination by a single immunizing dose. EFFECT: enhanced effectiveness of immunogenicity of vaccine. 11 cl, 4 tbl
Ferroptosis, a form of regulated cell death that is driven by iron-dependent phospholipid peroxidation, has been implicated in multiple diseases, including cancer1-3, degenerative disorders4 and organ ischaemia-reperfusion injury (IRI)5,6. Here, using genome-wide CRISPR-Cas9 screening, we identified that the enzymes involved in distal cholesterol biosynthesis have pivotal yet opposing roles in regulating ferroptosis through dictating the level of 7-dehydrocholesterol (7-DHC)-an intermediate metabolite of distal cholesterol biosynthesis that is synthesized by sterol C5-desaturase (SC5D) and metabolized by 7-DHC reductase (DHCR7) for cholesterol synthesis. We found that the pathway components, including MSMO1, CYP51A1, EBP and SC5D, function as potential suppressors of ferroptosis, whereas DHCR7 functions as a pro-ferroptotic gene. Mechanistically, 7-DHC dictates ferroptosis surveillance by using the conjugated diene to exert its anti-phospholipid autoxidation function and shields plasma and mitochondria membranes from phospholipid autoxidation. Importantly, blocking the biosynthesis of endogenous 7-DHC by pharmacological targeting of EBP induces ferroptosis and inhibits tumour growth, whereas increasing the 7-DHC level by inhibiting DHCR7 effectively promotes cancer metastasis and attenuates the progression of kidney IRI, supporting a critical function of this axis in vivo. In conclusion, our data reveal a role of 7-DHC as a natural anti-ferroptotic metabolite and suggest that pharmacological manipulation of 7-DHC levels is a promising therapeutic strategy for cancer and IRI.
Malaria is a preventable and treatable disease caused by Plasmodium species. In 2015, It was estimated that, about 1.8 million cases of malaria and about 400, 000 deaths were reported, 90% of which are in Africa. Those children who do not die may suffer brain damage or experience cognitive and learning deficits as a result of the disease severity. Though significant progress has been made in the last decade towards achieving global malaria targets, the disease burden is still relatively high in sub-Saharan African countries, especially among children \<5 years of age.

Injectable artesunate (Inj. AS) is a life-saving medication indicated for the treatment of severe/complicated malaria either intravenously or intramuscularly. The current version (3rd edition) of the World Health Organization (WHO) Guidelines for the Treatment of Malaria strongly recommends, based on high-quality evidence, that adults and children with severe malaria should be treated with "intravenous or intramuscular artesunate". Injectable Artesunate is prequalified under the WHO Prequalification Scheme. It has received marketing authorization in nearly all malaria-endemic countries and millions of doses have been distributed for use in the management of severe malaria.

Despite the widespread usage of Inj. AS, the safety database for the product is nearly empty with the WHO Individual Case Safety Reports (ICSR) database containing only 2622 reports to artesunate including Inj AS. Inj AS is considered a safe product even though there have been reports of rare but serious haematological reactions in relation to its use including post-treatment haemolysis and subsequent anaemia, some of them life-threatening and requiring blood transfusion. Experts agree that the benefits of Inj. AS far outweigh any risks it may pose and this formed the basis for the WHO recommendation for the use of Inj. AS as the first product of choice for treating severe malaria except where it is not available and in which case parenteral artemether is recommended conditionally. In view of the millions of doses of Inj AS deployed and used each year, it is important to undertake focused, intensive safety surveillance of the medicine to obtain continuous evidence on its benefits-risk profile and also to prevent undocumented or rare but serious adverse events acting as barriers to its uptake.

Apart from the detailed well-collected safety information obtained during clinical trials, there is no published information on the real-life safety experience of Inj. AS in large cohorts of patients. This study is therefore designed to obtain real-life safety experience of Inj. AS when used in actual practice settings in 4 African countries - Ethiopia, Ghana, Malawi and Uganda. The study is designed as a prospective, observational, longitudinal cohort study of patients administered Inj AS in the course of normal clinical practice. The method used is cohort event monitoring which has been deployed for the study of antimalarials and is being suggested as a key method for several post-authorisation safety studies
Beginning within 2 weeks prior to stereotactic radiosurgery, patients receive abemaciclib PO BID. Treatment continues in the absence of disease progression or unacceptable toxicity.
Magnesium transporter 1 (MAGT1) gene loss-of-function variants lead to X-linked MAGT1 deficiency with increased susceptibility to EBV infection and N-glycosylation defect (XMEN), a condition with a variety of clinical and immunological effects. In addition, MAGT1 deficiency has been classified as a congenital disorder of glycosylation (CDG) due to its unique role in glycosylation of multiple substrates including NKG2D, necessary for viral protection. Due to the predisposition for EBV, this etiology has been linked with hemophagocytic lymphohistiocytosis (HLH), however only limited literature exists. Here we present a complex case with HLH and EBV-driven classic Hodgkin lymphoma (cHL) as the presenting manifestation of underlying immune defect. However, the patient's underlying immunodeficiency was not identified until his second recurrence of Hodgkin disease, recurrent episodes of Herpes Zoster, and after he had undergone autologous hematopoietic stem cell transplant (HSCT) for refractory Hodgkin lymphoma. This rare presentation of HLH and recurrent lymphomas without some of the classical immune deficiency manifestations of MAGT1 deficiency led us to review the literature for similar presentations and to report the evolving spectrum of disease in published literature. Our systematic review showcased that MAGT1 predisposes to multiple viruses (including EBV) and adds risk of viral-driven neoplasia. The roles of MAGT1 in the immune system and glycosylation were highlighted through the multiple organ dysfunction showcased by the previously validated Immune Deficiency and Dysregulation Activity (IDDA2.1) score and CDG-specific Nijmegen Pediatric CDG Rating Scale (NPCRS) score for the patient cohort in the systematic review.
The invention relates to medicine, specifically to cosmetics, in particular to the production of hand treatment lotions. The aim of the invention is to improve the medical, cosmetic and consumer characteristics of said lotions. The inventive lotion has an equilibrium composition, provides a softening, cleaning, protective and tonic action, and enables bioactive components to penetrate the skin in an effective manner without an irritant, allergic effect. Said lotion comprises glycerin, ethyl alcohol, sodium bicarbonate, bioactive components (in particular, plantain juice, and/or kalanchoe juice, and/or a liquid extract of eleutherococcus, and/or fresh lemon juice, and/or pantocrine, and/or aloe juice, and/or a hypericum infusion, and/or a calendula infusion, and/or fresh apple juice) and essential oils in a defined correlation. Because of its low allergenicity, the lotion can be used several times a day and if necessary, after each contact with water. Said lotion enables persons with a sensitive skin to preserve the delicacy of their hands and provides comfort therefor, protecting the skin against negative environmental effects.
The caregivers of children who are deemed by a healthcare professional to be unable to answer questionnaires (group 2) will be invited to complete proxy-reported questionnaires only. There are no self-reported questionnaires for this group.
To ensure full fluorescence and patient comfort, the GloStrip® impregnated tip should be moistened with one or two drops of sterile, isotonic saline or irrigating solution before application.

Touch conjunctiva or fornix as required with moistened tip. It is recommended that the patient blink several times after application.

NOTE: The contents may not be sterile if the individual strip package has been damaged or previously opened. This product is intended for external use only. Keep out of reach of children. Store below 30°C.
Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. In most patients no benefit has been associated with using two RAS inhibitors concomitantly. In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function and electrolytes in patients on lisinopril and other agents that affect the RAS.

Do not co-administer aliskiren with lisinopril in patients with diabetes. Avoid use of aliskiren with lisinopril in patients with renal impairment (GFR <60 ml/min).
The invention provides orchid leaf cough-relieving granules. The granules are mainly used for lung-heat clearing, cough relieving and body fluid generating. The ingredients comprise orchid leaves, cortex mori, balloonflower root, bletilla striata, motherwort, loquat leaves, baikal skullcap root and sweet wormwood. The cough-relieving granules are prepared from the ingredients at certain weight ratios after drying, mixing and grinding processes. The granules are mainly used for lung-heat clearing and cough-relieving, and has functions of clearing heat, cooling blood, enriching yin, nourishing lung, treating dry cough and long cough, detoxifying and the like. The cough-relieving granules take full advantage of multiple pharmacological efficacies of orchid leaves and are an ideal cough-relieving medicine.
AGI-134 via IT injection. The proposed treatment is one dose of AGI-134 monotherapy per cycle; each cycle consists in three weeks, dosing will be given for 4 cycles.
Individually titrate ROXICODONE to a dose that provides adequate analgesia and minimizes adverse reactions. Continually reevaluate patients receiving ROXICODONE to assess the maintenance of pain control, signs and symptoms of opioid withdrawal, and other adverse reactions, as well as to reassess for the development of addiction, abuse, or misuse [see Warnings and Precautions (5.1, 5.14)]. Frequent communication is important among the prescriber, other members of the healthcare team, the patient, and the caregiver/family during periods of changing analgesic requirements, including initial titration.

If the level of pain increases after dosage stabilization, attempt to identify the source of increased pain before increasing the ROXICODONE dosage. If after increasing the dosage, unacceptable opioid-related adverse reactions are observed (including an increase in pain after a dosage increase), consider reducing the dosage [see Warnings and Precautions (5)]. Adjust the dosage to obtain an appropriate balance between management of pain and opioid-related adverse reactions.
The present invention relates to a toothpaste composition containing components of Houttuynia cordata, Saururus chinensis, Bauhinia forficata, and stevia. The toothpaste composition is prepared by forming mixed dough by further adding Houttuynia cordata powder to a mixture in which powder of Houttuynia cordata, Saururus chinensis, Bauhinia forficata, stevia, kelp, and Ulmus davidiana var. japonica NAKAI. root bark are mixed with solar salt, and anti-sodium sulfate powder; and incorporating said mixed dough, thereby completely removing foreign substances, dental plaque, nicotine, etc. from teeth and improving pleasant refreshment. The toothpaste composition is a multi-functional comprehensive healthy toothpaste composition having various effects: alleviating pneumonia and bronchitis, which is a pharmacological action of Houttuynia cordata; facilitating excretion of stool and urine, which is a pharmacological action of Saururus chinensis; helping to treat diabetes, which is a pharmacological action of Bauhinia forficata and stevia; providing antihypertensive action, which is a pharmacological action of kelp; and helping to treat gastrointestinal diseases, bronchitis, and rhinitis, which is a pharmacological action of Ulmus davidiana var. japonica NAKAI. root bark, thereby helping to prevent and ameliorate the overall adult diseases of modern people.
Participants in the control condition will take placebo (no drug) pill form, po, qhs, including instructions on dosage, expectations, and potential side effects for (16 nights taking a pill). Other assessments include self-report research questionnaires and cognitive testing, daily sleep diaries, and actigraphy.
PURPOSE: To evaluate natural language processing (NLP) methods to infer metastatic sites from radiology reports.
METHODS: A set of 4,522 computed tomography (CT) reports of 550 patients with 14 types of cancer was used to fine-tune four clinical large language models (LLMs) for multilabel classification of metastatic sites. We also developed an NLP information extraction (IE) system (on the basis of named entity recognition, assertion status detection, and relation extraction) for comparison. Model performances were measured by F1 scores on test and three external validation sets. The best model was used to facilitate analysis of metastatic frequencies in a cohort study of 6,555 patients with 53,838 CT reports.
RESULTS: The RadBERT, BioBERT, GatorTron-base, and GatorTron-medium LLMs achieved F1 scores of 0.84, 0.87, 0.89, and 0.91, respectively, on the test set. The IE system performed best, achieving an F1 score of 0.93. F1 scores of the IE system by individual cancer type ranged from 0.89 to 0.96. The IE system attained F1 scores of 0.89, 0.83, and 0.81, respectively, on external validation sets including additional cancer types, positron emission tomography-CT ,and magnetic resonance imaging scans, respectively. In our cohort study, we found that for colorectal cancer, liver-only metastases were higher in de novo stage IV versus recurrent patients (29.7% v 12.2%; P < .001). Conversely, lung-only metastases were more frequent in recurrent versus de novo stage IV patients (17.2% v 7.3%; P < .001).
CONCLUSION: We developed an IE system that accurately infers metastatic sites in multiple primary cancers from radiology reports. It has explainable methods and performs better than some clinical LLMs. The inferred metastatic phenotypes could enhance cancer research databases and clinical trial matching, and identify potential patients for oligometastatic interventions.
Increased Mortality in Elderly Patients with Dementia-Related Psychosis

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Chlorpromazine Hydrochloride Injection, USP is not approved for the treatment of patients with dementia-related psychosis (see BOXED WARNING).

The extrapyramidal symptoms which can occur secondary to chlorpromazine may be confused with the central nervous system signs of an undiagnosed primary disease responsible for the vomiting, e.g., Reye’s syndrome or other encephalopathy. The use of chlorpromazine and other potential hepatotoxins should be avoided in children and adolescents whose signs and symptoms suggest Reye’s syndrome.

Chlorpromazine Hydrochloride Injection contains sodium metabisulfite and sodium sulfite, sulfites that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.